UNC0631 (CAS 1320288-19-4)
QUICK LINKS
UNC0631 demonstrates remarkable potency and selectivity as an inhibitor of G9a activity both in vitro and in cellular contexts. In vitro, it exhibits a potent inhibitory effect on G9a activity with an IC50 of 4 nM, effectively impeding G9a/GLP-mediated dimethylation of histone 3 on lysine 9 in MDA-MB-231 cells with an IC50 of 25 nM. Its inhibitory prowess extends to various cancer cell lines and the human fetal lung IMR-90 cell line, effectively targeting G9a/GLP activity. UNC0631 stands out as a novel G9a inhibitor, showcasing exceptional potency across multiple cell lines while maintaining a significant separation between functional efficacy and cellular toxicity. The protein lysine methyltransferase G9a plays a pivotal role in transcriptional repression, employing H3K9me2 dimethylation of chromatin as well as nonhistone proteins.
UNC0631 (CAS 1320288-19-4) References
- Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. | Liu, F., et al. 2011. J Med Chem. 54: 6139-50. PMID: 21780790
- The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. | Hsiao, SM., et al. 2015. Ann Surg Oncol. 22 Suppl 3: S1556-65. PMID: 25613390
- Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. | Wang, HY., et al. 2019. Nucleic Acids Res. 47: 2349-2364. PMID: 30649550
- Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents. | Cao, H., et al. 2019. Eur J Med Chem. 179: 537-546. PMID: 31276898
- The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway. | Ma, W., et al. 2020. Hepatology. 72: 1283-1297. PMID: 31990985
- Upregulation of miR-101a Suppresses Chronic Renal Fibrosis by Regulating KDM3A via Blockade of the YAP-TGF-β-Smad Signaling Pathway. | Ding, H., et al. 2020. Mol Ther Nucleic Acids. 19: 1276-1289. PMID: 32092824
- Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit. | Yang, Z., et al. 2020. Front Cell Dev Biol. 8: 424. PMID: 32626701
- Activity Comparison of Epigenetic Modulators against the Hemoprotozoan Parasites Babesia divergens and Plasmodium falciparum. | Vanheer, LN. and Kafsack, BFC. 2021. ACS Infect Dis. 7: 2277-2284. PMID: 33599488
- High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. | Tatman, PD., et al. 2021. J Clin Med. 10: PMID: 34300316
- Histone demethylase KDM3C regulates the lncRNA GAS5-miR-495-3p-PHF8 axis in cardiac hypertrophy. | Zhao, L., et al. 2022. Ann N Y Acad Sci. 1516: 286-299. PMID: 35777757
- Augmented Production of Platelets From Cord Blood With Euchromatic Histone Lysine Methyltransferase Inhibition. | Liu, Y., et al. 2022. Stem Cells Transl Med. 11: 946-958. PMID: 35880582
- KDM3A promotes oral squamous cell carcinoma cell proliferation and invasion via H3K9me2 demethylation-activated DCLK1. | Yang, L., et al. 2022. Genes Genomics. 44: 1333-1342. PMID: 36094735
- Synergistic Effect of Combined Inhibition of the Checkpoint kinase 1 and G9a Methyltransferase Pathways in Pancreatic Cancer | Urrutia, G., Salmonson, A., & Lomberk, G. 2018. The FASEB Journal. 32: 835.1-835.1.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UNC0631, 5 mg | sc-397011 | 5 mg | $149.00 |